<DOC>
	<DOCNO>NCT00832481</DOCNO>
	<brief_summary>This 17 week , randomize , single center , open-label , parallel-group study compare glucose excursion efficacy safety parameter repaglinide thrice daily metformin thrice daily newly diagnose type 2 diabetes subject China .</brief_summary>
	<brief_title>Comparison Effects Repaglinide Metformin Glucose Excursions</brief_title>
	<detailed_description>This 17 week , randomize , single center , open-label , parallel-group study compare glucose excursion efficacy safety parameter repaglinide thrice daily metformin thrice daily newly diagnose type 2 diabetes subject China . Eligibility participation determine medical history , physical examination , laboratory result obtain screen visit ( see trail population ) . About 60 patient newly diagnose ( within 6 month ) type 2 diabetes insulin oral antidiabetic drug ( OAD ) naïve include study . All subject give informed consent start examination test . Then 24h blood glucose patient record utilizing continue glucose monitor system ( CGMS ) . Besides , follow data subject collect : HbA1c , Fasting blood glucose , 2h postprandial blood glucose , fast lipid profile , 2h postprandial lipid profile , fast uric acid , 2h postprandial uric acid , fast insulin proinsulin , 2h postprandial insulin proinsulin , fast C peptide , 2h postprandial C peptide , fast glucagon , 2h postprandial glucagon . After baseline data collect , eligible subject randomize group 2:1 ratio ( 40 repaglinide 20 metformin ) . IVGTT hyperinsulinemic-euglycemic clamp do 20 patient repaglinide group 10 patient metformin group ( le 20 % drop-off rate acceptable study ) . Follow , patient start receive either repaglinide thrice daily ( immediately breakfast lunch , dinner ) metformin thrice daily ( breakfast , lunch dinner ) . The initial repaglinide dos base HbA1c level day randomization ( 0.5 mg tid HbA1c &lt; 8 % 1 mg tid HbA1c ≥ 8 % ) ; initial dosage metformin 0.5 g tid dosage keep end study . Treatment diary ask every subject record glucose level ( 7 time per day 2 day per week first three week , 7 time per day 1 day per week end study ) , diet exercise , stress situation , hypoglycemic symptom . All patient follow visit clinic every week first three week , patient repaglinide group titrate dos . Dose adjustment aim achieve follow glycemic target : fast blood glucose : 4.4 - 6.0 mmol/L , 2h post prandial glucose 4.4 - 8.0 mmol/L . If glycaemic target achieve , repaglinide dose adjust every week ( see Schematic diagram trial design ) . The adjustment repaglinide dos base mean blood glucose record subject diary . The dos repaglinide meal may different , depend record blood glucose concentration . After three week titration repaglinide ( maximal dosage repaglinide 2 mg tid ) , patient group keep optimal dosage next 12 week . Clinic visit conduct every four week period dosages titration collect information , hypoglycemia , adverse event fast blood glucose . Complicated examination repeat 12 week treatment group , include physical examination , electrocardiogram ( ECG ) , CGMS , fast 2h post prandial glucose , concentration insulin , proinsulin , C peptide , glucagon , uric acid . IVGTT hyperinsulinemic-euglycemic clamp repeat subject begin study . Data collect analyze .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity . ( Trial relate activity procedure would perform normal management subject . ) 2 . Ages 2090 year 3 . BMI 18.5 30 kg/m2 4 . Newly diagnose type 2 diabetes . Type 2 diabetes accordance WHO criteria 1999 5 . The history diabetes less 6 month 6 . HbA1c &lt; 10 % . 7 . Only diet and/or exercise , OAD insulin naïve subject 1 . Any history OAD insulin therapy precede trial . 2 . Type 1 diabetic subject , include LADA 3 . Pregnant , breastfeed intention become pregnant use adequate contraceptive measure ( adequate contraceptive measure sterilisation , IUD , oral contraceptive barrier method ) and/or trial . 4 . Impaired hepatic function ( ALT &gt; 2.5 time upper limit local laboratory normal range ) 5 . Impaired renal function , define serum creatinine ≥ 1.5 mg/dl . 6 . Use systemic inhaled glucocorticoid medication know interfere glucose metabolism . 7 . Recently acute diabetic complication 8 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . 9 . Recently operation , injury , inflammation stress condition . 10 . Recently cardiac disease following :</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Repaglinide</keyword>
	<keyword>Metformin</keyword>
</DOC>